Novel targeted therapies for autoimmunity.

Published

Journal Article (Review)

The emergence of new targeted therapies is rapidly improving the treatment of autoimmune disease. These drugs have been variably designed to deplete specific T and B cell subsets, interrupt receptor-ligand interactions, and inhibit the activity of inflammatory mediators relevant to immune function. Abatacept, a co-stimulatory blocker, and rituximab, a B cell depleting antibody, are among the approved therapies seeking new indications, while the newer therapies include Fc receptor-non-binding CD3-specific antibodies, IL-12/23 antibodies, an IL-6 receptor antagonist, a sphingosine-1-phosphate agonist, and small molecule inhibitors of intracellular protein kinases. Antigen-specific therapies are in their infancy, but the latest results administering glutamic acid dehydrogenase peptide to type 1 diabetics are promising. In the future, treatment strategies may increasingly explore the use of drug combinations acting at multiple sites of aberrant immunoregulation to achieve disease quiescence and immune tolerance.

Full Text

Duke Authors

Cited Authors

  • St Clair, EW

Published Date

  • December 2009

Published In

Volume / Issue

  • 21 / 6

Start / End Page

  • 648 - 657

PubMed ID

  • 19828300

Pubmed Central ID

  • 19828300

Electronic International Standard Serial Number (EISSN)

  • 1879-0372

Digital Object Identifier (DOI)

  • 10.1016/j.coi.2009.09.008

Language

  • eng

Conference Location

  • England